Hyperthermic isolated perfusion with low-dose TNFα and doxorubicin in patients with locally advanced soft tissue limb sarcomas

Carlo Ricardo Rossi, M. Foletto, S. Mocellin, P. Pilati, L. Quintieri, G. L. De Salvo, D. Nitti, M. Lise

Research output: Contribution to journalArticlepeer-review

Abstract

We report here the results of 27 patients who underwent hyperthermic isolated limb perfusion with low-dose TNFα (1 mg) and doxorubicin (8.5 mg/l of limb volume) for locally advanced soft tissue sarcomas. A tumor response was observed in 85% of cases. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 82 and 85% of patients, respectively. Locoregional toxicity was low or mild in 14 patients, while 2 patients had severe limb toxicity. Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFα was 56. HILP with low-dose TNFα and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Keywords

  • Doxorubicin
  • Isolated limb perfusion
  • Locally-advanced soft tissue limb sarcomas
  • TNFα

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Hyperthermic isolated perfusion with low-dose TNFα and doxorubicin in patients with locally advanced soft tissue limb sarcomas'. Together they form a unique fingerprint.

Cite this